A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma



Status:Recruiting
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:6/7/2018
Start Date:November 16, 2017
End Date:December 15, 2019
Contact:Study Contact
Email:JNJ.CT@sylogent.com
Phone:844-434-4210

Use our guide to learn which trials are right for you!

A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Subjects With Relapsed or Refractory Multiple Myeloma

The main purpose of this study is to assess the safety of the combination of JNJ-63723283 and
daratumumab (Part 1); to compare the overall response rate (ORR) in participants treated with
JNJ-63723283 in combination with daratumumab versus daratumumab alone (Part 2); and to
compare progression-free survival (PFS) in participants treated with JNJ-63723283 in
combination with daratumumab versus daratumumab alone (Part 3).

This is a multi-phase study of JNJ-63723283 in combination with daratumumab compared with
daratumumab alone in participants with multiple myeloma who have received at least 3 prior
lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD)
or whose disease is double refractory to both a PI and an IMiD. The study consists of
Screening Phase (procedures performed within 28 days before enrollment), Open-Label Treatment
Phase (with End-of-Treatment Visit to occur 4 weeks after the last dose of study treatment)
and Follow-up phase (8 weeks after the last dose of study treatment). Ongoing safety
evaluation during Part 1 and Part 2 will be overseen by the Safety Evaluation Team (SET). In
Part 3, ongoing safety and efficacy evaluation will be performed by the Independent Data
Monitoring Committee (IDMC).

Inclusion Criteria:

- Have received at least 3 prior lines of therapy including a proteasome inhibitor (PI)
and an immunomodulatory agent (IMiD) in any order during the course of treatment for
multiple myeloma or have disease that is refractory to both a PI and an IMiD

- Evidence of a response (partial response [PR] or better based on investigator's
determination of response by International Myeloma Working Group [IMWG] criteria) to
at least 1 prior treatment regimen

- Documented measurable disease for multiple myeloma at screening as defined in protocol

- Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

- Contraceptive use by men or women should be consistent with local regulations
regarding the use of contraceptive methods for participants participating in clinical
studies

Exclusion Criteria:

- Received any of the following prescribed medications or therapies in the past:
Anti-CD38 antibody, including daratumumab, and/or Anti-PD-1 (programmed death-1) and
anti-PD-L1 (programmed death-ligand 1) antibodies

- Plans to undergo a stem cell transplant prior to progression of disease on this study
(these participants should not be enrolled to reduce disease burden prior to
transplant)

- History of malignancy (other than multiple myeloma) within 2 years prior to first
administration of study drug (exceptions are squamous and basal cell carcinomas of the
skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the
investigator, with concurrence with the sponsor's medical monitor, is considered cured
with minimal risk of recurrence within 3 years)

- Clinical signs of meningeal involvement of multiple myeloma

- Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in
1 second (FEV1) <50% of predicted normal or known moderate or severe persistent asthma
within the past 2 years, or uncontrolled asthma of any classification
We found this trial at
7
sites
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
(617) 636-5000
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
?
mi
from
Boston, MA
Click here to add this to my saved trials
4201 Belfort Road
Jacksonville, Florida 32216
(408) 293-2336
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Antwerpen, 2060
?
mi
from
Antwerpen,
Click here to add this to my saved trials
1601 Trinity Street
Austin, Texas 78701
?
mi
from
Austin, TX
Click here to add this to my saved trials
Louisville, Kentucky 40207
?
mi
from
Louisville, KY
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials